Dr. Barlow is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
423 E 23rd St
18086-aS
New York, NY 10010Phone+1 212-686-7500
Education & Training
New York Presbyterian Hospital (Columbia and Cornell Campus)Fellowship, Urologic Surgical Oncology, 2016 - 2018- New York Presbyterian Hospital (Columbia Campus)Residency, Urology, 2010 - 2016
Columbia University Vagelos College of Physicians and SurgeonsClass of 2010
Harvard UniversityBA, Biochemical Sciences, 2001 - 2005
Certifications & Licensure
NY State Medical License 2016 - 2026
American Board of Urology Urology
Clinical Trials
- Intravesicular Abraxane for Treatment-Refractory Bladder Cancer
- Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676) Start of enrollment: 2018 Dec 24
- A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-risk Non-muscle Invasive Bladder Cancer (HR-NMIBC) Start of enrollment: 2023 Mar 23
Publications & Presentations
PubMed
- 17 citationsThe Cytidine Deaminase APOBEC3G Contributes to Cancer Mutagenesis and Clonal Evolution in Bladder Cancer.Weisi Liu, Kevin P Newhall, Francesca Khani, LaMont Barlow, Duy Nguyen
Cancer Research. 2023-02-15 - EDITORIAL COMMENT.LaMont J Barlow
Urology. 2022-04-01 - Editorial Comment.LaMont J Barlow, Gary D Steinberg
The Journal of Urology. 2021-11-01
Press Mentions
Bringing Bladder Cancer into FocusApril 2nd, 2017
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
